Company profile
Bionik Laboratories Corp.
OTC: BNKL · Healthcare · Medical - Care Facilities
#813 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ 59GM —SS 29
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), filing timeliness · ↓ market scale, Altman-Z
Methodology →Revenue TTM
$1.8M
Rev growth YoY (TTM)
+41.7%
Net income (FY)
-$4.9M
Employees
12
as of 2026-08-31
Market cap
$1.2k
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.8M$1.8M2023
Net income-$4.9M-$4.9M2023
Operating income-$4.8M-$4.8M2023
Total assets$3.4M$3.4M2023
Liabilities$5.0M$5.0M2023
Equity-$1.6M-$1.6M2023
Revenue trend
FY2014 – FY2023 · USD
FY14
FY17
FY17
FY18
FY21
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Bionik Laboratories Corp.’s revenue?
Bionik Laboratories Corp. booked $1.8M in FY2023 revenue, growing 42% year over year — faster than most Healthcare companies we track, at a -274.0% net margin.
Peers · Healthcare
BioRegenx, Inc.30DInnovative MedTech Inc.49DBeleave Inc.——Nutranomics, Inc.——CanaFarma Hemp Products Corp.——Spectral Medical Inc31DNeighbors
Middlesex →Key facts
CEORichard Paul Russo Jr.
SectorHealthcare
IndustryMedical - Care Facilities
HeadquartersWatertown, MA
ExchangeOTC: BNKL
Employees12
IPO date2015-03-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.